Author

R. Haupt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Assay:proteomics· 3 Organism:human· 2 Organism:non-human primate· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

S. Weston· 4 shared J. Logue· 3 shared M. Frieman· 3 shared B. Zhou· 2 shared G. Glenn· 2 shared G. Smith· 2 shared H. Zhou· 2 shared J.-H. Tian· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

S. Weston

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants

J. Logue, R. Johnson, N. Patel, B. Zhou, S. Maciejewski, H. Zhou, A. Portnoff, J.-H. Tian, M. McGrath, R. Haupt, S. Weston, H. Hammod, M. Guebre-Xabier, C. Dillen, J. Plested, , M. Frieman

This study evaluates a nanoparticle vaccine against SARS-CoV-2 variants, showing it induces strong immune responses and protection in mice and baboons against multiple variants.

bioRxiv · Jun 8, 2021 · PreprintImmunology

IDENTIFICATION OF BIOCHEMICAL AND MOLECULAR MARKERS OF EARLY AGING IN CHILDHOOD CANCER SURVIVORS

S. Ravera, T. Vigliarolo, S. Bruno, F. Morandi, D. Marimpietri, F. Sabatini, M. Dagnino, A. Petretto, M. Bartolucci, M. Muraca, E. Biasin, R. Haupt, M. Zecca, F. Fagioli, D. Cilloni, , F. Frassoni

This study identifies biochemical and molecular markers of early aging in childhood cancer survivors through analysis of metabolic and mitochondrial alterations.

bioRxiv · Apr 1, 2021Cancer Biology

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice

J.-H. Tian, N. Patel, R. Haupt, H. Zhou, S. Weston, H. Hammond, J. Lague, A. D. Portnoff, J. Norton, M. Guebre-Xabier, B. Zhou, K. Jacobson, S. Maciejewski, R. Khatoon, M. Wisniewska, , G. Smith

This study evaluates the immunogenicity and protective efficacy of the NVX-CoV2373 SARS-CoV-2 vaccine in baboons and mice, showing strong immune responses and protection without enhanced disease.

bioRxiv · Jun 29, 2020Microbiology

Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics

L. Si, H. Bai, M. Rodas, W. Cao, C. Y. Oh, A. Jiang, R. Moller, D. Hoagland, K. Oishi, S. Horiuchi, S. Uhl, D. Blanco-Melo, R. A. Albrecht, W.-C. Liu, T. Jordan, , D. E. Ingber

This paper demonstrates the use of human organ chips to rapidly repurpose therapeutics for viral pandemics, identifying amodiaquine as a potential treatment for SARS-CoV-2.

bioRxiv · Apr 13, 2020 · PreprintMicrobiology

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo

S. Weston, C. M. Coleman, R. Haupt, J. Logue, K. Matthews, M. Frieman

This study evaluates 20 FDA-approved drugs for antiviral activity against SARS-CoV-2 and SARS-CoV, finding 17 inhibit SARS-CoV-2 at non-cytotoxic concentrations and two protect mice from SARS-CoV disease.

bioRxiv · Mar 25, 2020 · PreprintMicrobiology